Etanercept Survival in Elderly Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02503059

Enrollment

Registered

2015-07-20

Start date

2014-11-30

Completion date

2015-02-28

Last updated

2015-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified. All variables were collected through retrospective review of medical records of patients dermatology unit are made.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs) defined by: PASI(Psoriasis Area and Severity Index)\> 10 and / or BSA(Body Surface Area)\> 10% and / or DLQI(Dermatology Life Quality Index)\> 10 * PASI\> 10 and / or BSA(Body Surface Area)\> 10% and / or DLQI(Dermatology Life Quality Index)\> 10 * Over 60 years of age at the start of treatment * Receiving etanercept at any time * Available history in the Dermatology

Exclusion criteria

* Patients with insufficient clinical data in the medical record

Design outcomes

Primary

Measure	Time frame	Description
primary ineffectiveness in patients with etanercept treatment	24 weeks	Number of participants not achieve PASI 50 response at 12 weeks
Secondary ineffectiveness in patients with etanercept treatment	24 weeks (duration of treatment with etanercept)	Number of participants with Poor adherence to treatment with etanercept,
Ineffectiveness of treatment in localized lesions in patients with etanercept treatment	24 weeks(duration of treatment with etanercept)	Despite having achieved a good response PASI no improvement in critical injuries

Secondary

Measure	Time frame
Number of participants with adverse events during treatment with etanercept	24 weeks
number of participants with Conditions requiring hospitalization and / or surgery	24 weeks
Number of participants with disease remission	24 weeks
number of participants with Poor adherence to treatment with etanercept	24 weeks

Countries

Spain

Outcome results